Comments on: ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

Comments on: ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) https://enterabio.com/news/endo-2026-oral-presentation-highlights-comparative-clinical-data-for-enteras-breakthrough-single-tablet-eb613-first-in-class-oral-pth1-34-anabolic-for-osteoporosis/ Global Leader in Oral Delivery of Therapeutic Proteins Tue, 16 Jun 2026 06:16:53 +0000 hourly 1 https://wordpress.org/?v=6.9.4